Assessing efgartigimod dosing patterns and Myasthenia Gravis Activities of Daily Living outcomes in clinical practice: results from a large patient support program database.
People with myasthenia gravis using efgartigimod saw real-world symptom improvements similar to trial results, even with varied dosing.
Real-world efgartigimod dosing patterns in MG show heterogeneity from clinical trial protocols, but MG-ADL score improvements were sustained in clinical practice, validating treatment effectiveness beyond trial conditions. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Real-world retrospective cohort (large patient support program database)
- Category
- Other
- Maturity
- Validated
- Journal
- Frontiers in neurology
Why it surfaced
Real-world validation of a recently approved rare disease therapy (efgartigimod for MG) from a large database; open-access; authored by leading MG experts including Wolfe GI (principal MGTX trialist); provides actionable real-world efficacy data for prescribers.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.